Journal of Inherited Metabolic Disease

, Volume 32, Issue 3, pp 395–399 | Cite as

Newborn blood spot screening: New opportunities, old problems

Newborn Screening Revisited

Summary

Newborn screening is evolving very rapidly. Geographical coverage is expanding, particularly for common disorders such as congenital hypothyroidism. New technologies, particularly tandem mass spectrometry and high throughput mutation analysis, have increased greatly the range of disorders which could be covered. However, these new possibilities are being exploiting at very different rates in different countries. This is due in part to the different ways in which generally-accepted screening criteria, based on the ten principles of Wilson and Jungner, are being interpreted and applied to policy. The appropriate management of some of the conditions newly-detectable by screening also remains controversial and there is a pressing need to align screening policy and clinical practice. Critical analysis and careful collection of data on an international basis are required to resolve these issues.

References

  1. American College of Medical Genetics. Newborn Screening Working Group (2006) Newborn screening: towards a uniform screening panel and system. Genet Med 8(Supplement): 1S–252SCrossRefGoogle Scholar
  2. Bodamer OA, Hoffmann GF, Lindner M (2007) Expanded newborn screening in Europe 2007. J Inherit Metab Dis 30: 439–444PubMedCrossRefGoogle Scholar
  3. Borrajo GJC (2007) Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis 30: 466–481PubMedCrossRefGoogle Scholar
  4. Bowling FG, McGill JJ, Shepherd RW, Danks DM (1990) Screening for cystic fibrosis: use of delta F508 mutation. Lancet 1: 925–926CrossRefGoogle Scholar
  5. Buist RM, Huntingdon K (2007) Scene from the USA: the illogic of mandating screening without also providing for treatment. J Inherit Metab Dis 30: 445–446PubMedCrossRefGoogle Scholar
  6. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF (1993) Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39: 66–71PubMedGoogle Scholar
  7. Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN (2007) Quantification of hemoglobin A2 by tandem mass spectrometry. Clin Chem 53: 1448–1454PubMedCrossRefGoogle Scholar
  8. deWilde A, Sadilkova K, Sadilek M, Vasta V, Hahn SH (2008) Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography–tandem mass spectrometry: application to newborn screening. Clin Chem 54: 1961–1968PubMedCrossRefGoogle Scholar
  9. Dhondt JL (2007) Neonatal screening: from the ‘Guthrie age’ to the ‘genetic age’. J Inherit Metab Dis 30: 418–422PubMedCrossRefGoogle Scholar
  10. Dobrowolski SF, Banas RA, Suzow JG, Berkley M, Naylor EW (2003) Analysis of common mutations in the galactose-1-phosphate uridyl transferase gene: new assays to increase the sensitivity and specificity of newborn screening for galactosemia. J Mol Diagn 5: 42–47PubMedGoogle Scholar
  11. Dobrowolski SF, Ellingson CE, Caldovic L, Tuchman M (2007) Streamlined assessment of gene variants by high resolution melt profiling utilizing the ornithine transcarbamylase gene as a model system. Hum Mutat 28: 1133–1040PubMedCrossRefGoogle Scholar
  12. Downing M, Pollitt RJ (2008) Newborn screening in the UK—past, present and future. Ann Clin Biochem 45: 11–17PubMedCrossRefGoogle Scholar
  13. Frazier DM, Millington DS, McCandless SE, et al (2006) The tandem mass spectrometry newborn screening experience in North Carolina: 1997–2005. J Inherit Metab Dis 29: 76–85PubMedCrossRefGoogle Scholar
  14. Fukushi M (2007) An international training and support programme for the establishment of neonatal screening in developing countries. J Inherit Metab Dis 30: 593–595PubMedCrossRefGoogle Scholar
  15. Gelb MH, Turecek F, Scott CR, Chamoles NA (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 29: 397–404PubMedCrossRefGoogle Scholar
  16. Gregersen N, Andresen BS, Pedersen CB, Olsen RKJ, Corydon TJ, Bross P (2008) Mitochondrial fatty acid oxidation defects—remaining challenges. J Inherit Metab Dis 31: 643–657PubMedCrossRefGoogle Scholar
  17. Guthrie R (1980) Organisation of a regional newborn screening laboratory. In: Bickel H, Guthrie R, Hammersen G, eds. Neonatal Screening for Inborn Errors of Metabolism. Berlin: Springer-Verlag, 259–270Google Scholar
  18. Janzen N, Peter M, Sander S, et al (2007) Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography–tandem mass spectrometry. J Clin Endocrinol Metab 92: 479–485Google Scholar
  19. Howell RR, Engelson G (2007) Structures for clinical follow-up: newborn screening. J Inherit Metab Dis 30: 600–605PubMedCrossRefGoogle Scholar
  20. Khneisser I, Adib SM, Megarbane A, Lukacs Z (2009) International cooperation in the expansion of a newborn screening programme in Lebanon: a possible model for other programmes. J Inherit Metab Dis. doi: 10.1007/s10545-008-1008-5 Google Scholar
  21. Koch R (1980) Medical backup needed for newborn screening programmes. In: Bickel H, Guthrie R, Hammersen G, eds. Neonatal Screening for Inborn Errors of Metabolism. Berlin: Springer-Verlag, 271–273Google Scholar
  22. Lindner M, Abdoh G, Fang-Hoffmann J, et al (2007) Implementation of extended neonatal screening and a metabolic unit in the state of Qatar: developing and optimising strategies in cooperation with the neonatal screening centre in Heidelberg. J Inherit Metab Dis 30: 522–529PubMedCrossRefGoogle Scholar
  23. Lindner M, Ho S, Kölker S, Abdoh G, Hoffmann GF, Burgard P (2008) Newborn screening for methylmalonic acidurias—optimization by statistical parameter combination. J Inherit Metab Dis 31: 379–385PubMedCrossRefGoogle Scholar
  24. Loeber JG (2007) Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis 30: 430–438PubMedCrossRefGoogle Scholar
  25. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P (2007) Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: The Mayo Clinic experience (2004–2007). J Inherit Metab Dis 30: 585–592PubMedCrossRefGoogle Scholar
  26. Millington DS, Kodo N, Norwood DL, Roe CR (1990) Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 13: 321–324PubMedCrossRefGoogle Scholar
  27. Padilla CD, Therrell BL (2007) Newborn screening in the Asia Pacific region. J Inherit Metab Dis 30: 490–506PubMedCrossRefGoogle Scholar
  28. Pollitt RJ (2006) International perspectives on newborn screening. J Inherit Metab Dis 29: 390–396PubMedCrossRefGoogle Scholar
  29. Pollitt RJ (2007) Introducing new screens: Why are we all doing different things? J Inherit Metab Dis 30: 423–429PubMedCrossRefGoogle Scholar
  30. President’s Council on Bioethics (2008) The changing moral focus of newborn screening: an ethical inquiry by the President’s Council of Bioethics. http://www.bioethics.gov/reports/newborn_screening/index.html (accessed 30/01/2009)
  31. Saadallah AA, Rashed MS (2007) Newborn screening: experiences in the Middle East and North Africa. J Inherit Metab Dis 30: 482–849PubMedCrossRefGoogle Scholar
  32. Solanki KK (2007) Training programmes for developing countries. J Inherit Metab Dis 30: 596–599PubMedCrossRefGoogle Scholar
  33. Therrell BL, Adams J (2007) Newborn screening in North America. J Inherit Metab Dis 30: 447–465PubMedCrossRefGoogle Scholar
  34. Torressani T, Biason-Lauber A (2007) Congenital adrenal hyperplasia: diagnostic advances. J Inherit Metab Dis 30: 563–575CrossRefGoogle Scholar
  35. Valle D, Manolio T (2008) Applying genomics to clinical problems—diagnostics, preventive medicine, pharmacogenetics. A white paper for the National Human Genome Research Institute. http://www.genome.gov/About/Planning (accessed 30/01/2009)
  36. van Spronsen FJ, Kiær Ahring K, Gizewska M (2009) PKU—What is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J Inherit Metab Dis 32: 58–64PubMedCrossRefGoogle Scholar
  37. Walter JH, Patterson A, Till J, et al (2009) Bloodspot acylcarnitine and amino acid analysis in cord blood samples; efficacy and reference data from a large cohort study. J Inherit Metab Dis 32: 95–101PubMedCrossRefGoogle Scholar
  38. Wilcken B (2007) Newborn screening for cystic fibrosis: Techniques and strategies. J Inherit Metab Dis 30: 537–543PubMedCrossRefGoogle Scholar
  39. Wilcken B (2008) The consequences of extended newborn screening programmes: Do we know who needs treatment? J Inherit Metab Dis 31: 173–177CrossRefGoogle Scholar
  40. Zhang XK, Elbin CS, Chuang WL, et al (2008) Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 54: 1725–1728PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Newborn Screening LaboratoryThe Children’s HospitalSheffieldUK

Personalised recommendations